Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Ok, most accounts are set up as margin.
If you have a margin account and have outstanding margin then they can borrow shares without permission, read the fine print.
Renmember the cost to shareholders when we were attacked by MAKO, shareholders losdt millions, I am still working off the losses is=n my tax filings after replacing the shares I bought at $3.00 plus, Had a bunch bac then. Of course I have many times over that number now. I also believe the crooks ( possibly financed by some of the BP'S) attempted to stop IPIX using whatever tactics it took.
Does this sound familar? ( should be Manipulating penny stocks)
Twitter User ‘Alexander Delarge’ Charged for Hyping Penny Stocks
https://finance.yahoo.com/news/twitter-user-alexander-delarge-charged-170842614.html
Matt Robinson and Christian Berthelsen
Tue, October 26, 2021, 1:08 PM·2 min read
In this article:
Explore the topics mentioned in this article
(Bloomberg) -- The man behind a popular Twitter account that promoted penny stocks was criminally charged for touting securities while simultaneously dumping shares, the latest sign that authorities are setting their sites on the social-media frenzy that’s invaded U.S. equity markets.
Steven Gallagher, 50, was taken into custody in Ohio Tuesday for running a pump-and-dump scheme that netted him more than $1 million through the Twitter handle, @AlexDelarge6553, according to a criminal complaint filed in federal court in Manhattan. Gallagher, who has touted at least 60 companies since the end of 2019, continued the manipulative conduct even after his brokerage firm closed his account, the Securities and Exchange Commission alleged in a parallel civil case.
Gallagher’s alias, Alexander Delarge, is the name of the sociopathic gang leader who Malcolm McDowell played in the 1971 film “A Clockwork Orange.” The 655321 figure Gallagher includes in his Twitter handle was the prison number for McDowell’s character in the movie. It wasn’t immediately clear whether Gallagher had retained a lawyer to respond to the government’s charges.
This year’s wild trading of meme stocks has been a focus for the SEC, which wants to make sure the army of retail investors who’ve taken to buying and selling shares aren’t getting fleeced. A particular target has been penny stocks. In February, the regulator suspended 15 stocks from trading due to concerns that their prices were being artificially inflated through social media by scammers.
Read more: SEC Suspends Trading in 15 Stocks That Got Hyped on Social Media
Gallagher traded over-the-counter stocks, including SpectraScience Inc, SPO Global Inc. and Alpine Holdings Inc.. Prosecutors say he amassed large positions, took to Twitter to promote the companies and then secretly sold his positions as other investors piled in. All the while, he publicly claimed he was in for the long haul.
In the SpectraScience trade, for example, Gallagher allegedly coordinated with other traders to buy shares in the defunct company, which hasn’t filed SEC financial statements since 2017. Gallagher acquired more than 20 million shares of the penny stock and touted it in a series of colorful tweets, showing purported screenshots of his brokerage orders, according to the criminal complaint filed by Manhattan federal prosecutors. He sold while continuing to promote the shares, writing: “Haven’t sold a share yet!”
Most Read from Bloomberg Businessweek
The Dane,
"It seems pretty clear cut…” An antibiotic compound named Brilacidin was proven most likely by the AI model to be able to combat the virus. From other predictive modelling studies, there is a host of data that supports that Brilacidin can effectively treat COVID-19, and the compound has now received FDA Fast Track designation for potential treatment.”
Next approval, EUA?
FB, They are finally reading your post of the month should be stickied!:
frenchbroad Tuesday, 10/26/21 11:31:21 AM
Re: None 0
Post #
380192
of 380233
Maybe some investment from Qatar today.
*An antibiotic compound named Brilacidin was proven most likely by the AI model to be able to combat the virus. From other predictive modelling studies, there is a host of data that supports that Brilacidin can effectively treat COVID-19, and the compound has now received FDA Fast Track designation for potential treatment.*
From here: https://aijourn.com/ai-driven-machine-learning-is-revolutionising-health-research/
*Dr Faisal Farooq
Dr Faisal Farooq, Head of Digital Health and Precision Medicine at Qatar Foundation’s Qatar Computing Research Institute (QCRI), discusses how AI-driven machine learning is helping to tackle COVID-19 and will impact the future of health research*
FB, You can't get an endorsement any more specific than that, thanks for the link
Organized crime is rampant wherever the democrats control, Washington DC is the headquarters run by the seditious democrat mafia and its not puppet Joe Biden. He is only the dummy at the end of the strings.
Over 80% of the patients were in Russia so they would have to make a deal to have Russia bury it to, don't believe it will happen to many foreign countries are now aware of Brilacidin.
Another PR link:
https://www.wallstreet-online.de/nachricht/14573410-innovation-pharmaceuticals-covid-19-clinical-trial-topline-results-anticipated-to-be-reported-the-week-of-november-8th
Do we really want another BP partnership? If Alphasigma is an example of a BP partnership, think of how long it would take for the companies who are selling the pokes to activate the next phase for Brilacidin, would they really want to end their Vaccine gravy train, by producing a Therapeutic like Brilacidin? I would prefer a buyout or go it alone if the phase II is successful.
No way of knowing how many compassionate use patients there are, but the FDA and I would assume Leo, would have that data available for study. With a SI of 426 may have motivated them to get back to the labs for testing the other Virus strains.
Leo isn't taking a couple more weeks, Leo said initally that the Data Lock would happen mid to late Oct. and Top line would be within the next 7 days. The 1st and 2nd are Sat and Sunday, Nov.6th and 7th are Sat. and Sunday (which would be the 7th day), weekend dates and the 8th falls within his predicted parimiters, however, there are 4 more days in the week of Nov 8th. We shall see! Give it a break!
Passed away!
I lost a friend last Thursday from a perforated bowel and Sepis. Died two days after learning his Bowel had been perferated.
Billy10us, I believe AS has the first right for IBD not for the Virus therapeutic as I remember?
First hand info: http://www.ipharminc.com/expanded-access-and-compassionate-use
Looking forward to your upcoming lectures after becoming the expert.
You don't know? Damn, I thought you knew everything!
THink CV is going to go away soon?
Moderna, Pfizer forecast for a combined $93.2B in COVID vaccine sales in 2022 - Ft
Source: Seeking Alpha
JFM, Thanks for the update, Compassionate use, has so may hoops one has to go through, its a wonder any patient survives long enough to even be treated.
Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7694556/
Some hope remains:
What is CTAP?
FDA has created a special emergency program for possible coronavirus therapies, the Coronavirus Treatment Acceleration Program (CTAP). The program uses every available method to move new treatments to patients as quickly as possible, while at the same time finding out whether they are helpful or harmful. We continue to support clinical trials that are testing new treatments for COVID so that we gain valuable knowledge about their safety and effectiveness. Please see our Frequently Asked Questions page for more information on the program.
https://www.fda.gov/drugs/coronavirus-covid-19-drugs/coronavirus-treatment-acceleration-program-ctap
Government should make EUA available to every person entering the hospital over 65 yoa elgiable.
I believe the Expanded / compassionate use by the FDA, the results could propell us into EUA the FDA is collecting results and may have them available for release with the top line results. It appears there are a number of Hospitals adminstering Brilacidin under the Compassionate use right to try provisions. Would be great to have a couple of hundred patients reports of recovery with the use of Brilacidin released with TLR.
I saw that, but thought it would remind the MAKO supporters that there are still risk of reporting false and misleading stories.
The links were provided by "the family man".
MAKO makes the news: https://iapps.courts.state.ny.us/nyscef/ViewDocument?docIndex=pIKsFTWq6bTkeqJwsPwYew==
Don't know excactly what to make of it as court cases are often long and drawn out.
MAKO makes the news: https://iapps.courts.state.ny.us/nyscef/ViewDocument?docIndex=pIKsFTWq6bTkeqJwsPwYew==
May be old
Great post xoc, should be stickied!
People know:
Friend,
We have an invasion at our Southern Border! If you think they aren't coming for us next, you're either painfully naive or deliberately want to see a terror attack on our soil.
Democrats have been trying to force in as many illegal immigrants as possible as quickly as possible. Two-year-olds are getting forced off planes for not wearing masks while Mayorkas just released 12,000+ illegals into the country without so much as a COVID test.
To top it off, they already tried to slip amnesty into their $3.5 trillion budget and shove it through as fast as possible. I've been harping on this kind of travesty for a while, and the rubber is about to hit the road. And there's a dumpster fire in the middle of the road.
They want to give ILLEGALS the right to remain in a country they broke into without any input from Republicans. Biden has no problem chartering free buses to transport illegals from the Southern Border all across America while trying to stifle and jab American citizens with vaccines and masks!?! Friend, we just drafted a petition to stop the border invasion, and we need your signature NOW.
Sign: No More Illegals at the Border >>
Their agenda is a clear message that Democrats care more about helping immigrants who break the law than citizens who are struggling for their family's safety. Can you take a couple of seconds to sign and stop the border invasion?
If they were proud to give amnesty when it wasn't legal, imagine how much worse it will be when they break down the floodgates permanently.
We stand against ANY allowance for illegal immigration.
Friend, an emergency situation like this requires emergency action. Do you have 30 seconds right now to sign for our fight against the invasion at the Southern Border?
For Freedom,
Team Boebert
Americas destructive forces are openly supporting the fall of our Democratic Republic with impunity. There is no doubt, based on the espeonage, tyranny outright treasonous acts by the Biden Administration (like the unchecked invasion from the south, pure treason) they know there are enough Soros, supported Attorneys, running the FBI, CIA, DOJ and many of the subversive bureaucracies, that they will never be prosecuted for their crimes.
Just consider all the alledged criminal acts Joe Biden, his facilitators, (including Hunter Biden) have been disclosed, during the last several years, the Russia/ China/ Ukrain exposure of bribery, money laundering and out right open treasonous acts and nothing happens to them, they have illegitimately taken over the control of Americin in the most corrupt coup of all times, nothing happens, Hugo Chavez took over Venezeula in a similar manner.
Hundreds of stories appears here on IHUB of hundreds of alledged criminal acts by democrat politicians generally viewed as "nothing to see here, next story". I realize everyone here is aware of our oppression and the criminal takeover happening, destroying our Liberty and Freedom, and America, so what can be done to change the destructive course we are on? Has to be soon or it will be to late!!! JMO from my observations.
That must be some back yard, 1.26986264 oz per Cu yard would be one hell of a deposit. Parker Schnable, would be all over it.He runs about 300 Cu yards per hr, or $685,725.00 (rounded) per hr.
That depends, if it supports IPIX well..................Maybe not
Yep been using that since before IHUB, other boards. Is there a problem, never hid the fact.
Great, now they are promoting a drug the ngives Cancer not cures cancer,WHERE CAN I BUY THIS I WANT IT NOW! LOL
Nothing like building a cliental for future sales of their anticancer drugs, huh?
Brilacidin COVID-19 Therapeutic
Authored byStaff
Updated September 14, 2021
Last reviewedSeptember 14, 2021
Fact checked byRobert Carlson, MD + Holly Lutmer PharmD
Brilacidin COVID-19 Antiviral Description
Innovation Pharma Brilacidin is a Host Defense Protein (HDP) mimetic representing a new drug class with antiviral, anti-inflammatory, and anti-bacterial properties.
Brilacidin (PMX-30063) is a synthetic, non-peptidic small molecule that kills pathogens swiftly, significantly reducing drug resistance development. Brilacidin also functions in a robust immunomodulatory capacity, lessening inflammation, and promoting healing. In addition, Brilacidin has the potent ability to inhibit coronaviruses, primarily by disrupting viral integrity and blocking viral entry.
Brilacidin is one of the few drugs targeting COVID-19 tested in human trials for other clinical indications. In addition, laboratory testing at independent laboratories supports Brilacidin’s antiviral ability to safely and potently inhibit SARS-CoV-2 and multiple strains of human coronaviruses. For example, in a human lung cell line against the SARS-CoV-2 betacoronavirus, Brilacidin achieved a Selectivity Index of 426.
Modeled after HDPs, the “front-line” of defense in the body's innate immune system is a synthetic, non-peptidic small molecule that kills pathogens swiftly, significantly reducing the likelihood of drug resistance developing.
On February 9, 2021, the journal Cell Culture published a paper that concluded Brilacidin was shown to exert potent inhibitory effects on SARS-CoV-2 in cell culture by decreasing viral load in different cell types, including ACE2 positive human lung cells, and, importantly, in both the Washington and Italian strains of the coronavirus. Testing of Brilacidin against additional SARS-CoV-2 virus strains is planned, concluded this paper.
A peer-reviewed article in Viruses supporting Brilacidin’s COVID-19 treatment potential can be accessed at this link.
Brilacidin and related compounds are protected under various compositions and use patents. A patent was filed and is pending for HDP-mimetics in the prophylaxis and/or treatment of inflammatory diseases of the gastrointestinal tract. Another patent for compounds for use in the treatment of mucositis has been awarded numerous global protections. Click here for a bibliography on the development of Brilacidin and the HDP-mimetics program.
ChemSpider ID: 28651526; Formula: C40H50F6N14O6; PubChem CID: 25023695; Brilacidin EPA: 1224095-98-0 | DTXSID90153594
Brilacidin COVID-19 Antiviral History
Innovation Pharma (OTCQB: IPIX) is developing Brilacidin for COVID-19 under Fast Track designation from the U.S. Food and Drug Administration (FDA) and is currently enrolling patients in Phase 2 clinical trial Brilacidin for treatment of moderate-to-severe COVID-19 in hospitalized patients (NCT04784897; updated April 19, 2021).
Innovation Pharma is developing Brilacidin for COVID-19 under Fast Track designation from the U.S. FDA. Upon recently completing a scheduled review of interim safety data from the trial, an independent Data Monitoring Committee recommended increasing the dosing regimen of Brilacidin from 3 days to 5 days of treatment, which may maximize therapeutic benefits and provide a comparison with 5-day remdesivir (Veklury), currently the only FDA-approved treatment for COVID-19.
A non-peer-reviewed study reported on October 30, 2020, Brilacidin Exhibits Potent In Vitro Antiviral Activity Against the SARS-CoV-2 virus.
On December 21, 2020, Innovation Pharmaceuticals announced that the U.S. FDA had approved the Company’s Investigational New Drug application to initiate a Phase 2 clinical trial.
On April 5, 2021, Leo Ehrlich, CEO at Innovation Pharmaceuticals, stated in a press release, “There is a sense of urgency to develop novel pan-coronavirus therapeutics for COVID-19, particularly given the growing spread of variants worldwide, including P1 and B.1.1.7, which appear to be contributing to cases of infection cropping up in patients who have already been vaccinated. With its unique mechanism of action to directly disrupt the novel coronavirus, we believe Brilacidin possesses the potential to address these worrisome reminders that SARS-CoV-2 isn’t going anywhere. More broadly, Brilacidin’s antiviral potency also appears to extend beyond coronaviruses to other types of viruses, based on independent ongoing laboratory research, further supporting Brilacidin’s broad-spectrum antiviral potential.”
“Taken together, the results from ongoing lab research into Brilacidin’s antiviral properties by different groups of scientists only strengthens our belief in Brilacidin,” said Leo Ehrlich, CEO, in a press statement issued on August 2, 2021. “With a highly contagious virus circulating throughout the world and continuing to mutate in dangerous ways, reducing the effectiveness of available COVID-19 treatments and vaccines, there is a global public health need to develop broad-spectrum antivirals. Our hope is that Brilacidin, which is showing an inherent ability to be resistant to viral mutations, can play a vital role in helping contain the spread of SARS-CoV-2, as the virus is likely to be an infectious disease challenge for years to come.”
Headquartered in Wakefield, Massachusetts, Innovation Pharmaceuticals Inc. (formerly Cellceutix Corporation) is a publicly-traded biopharmaceutical company (OTCQB: IPIX) dedicated to discovering and advancing innovative medical therapies in dermatology, oncology, anti-inflammatory, antibiotic, and antiviral applications.
Brilacidin COVID-19 Antiviral Indication
Brilacidin COVID-19 therapeutic candidate is a broad-spectrum antiviral for treating common colds and coronavirus infections. Brilacidin is an antibiotic that disrupts bacterial cell membranes, mimicking defensins that play a role in innate immunity.
Upon rinsing with the brilacidin oral rinse, brilacidin imitates defensin as a human HDP and binds to and disrupts the bacterial cell membrane. This causes bacterial cell membrane lysis and leakage of cellular cytoplasmic contents. This inhibits bacterial activity and may prevent or treat radiation-induced mucositis. Defensins, a family of antimicrobial and cytotoxic peptides expressed mainly by epithelial cells and neutrophils, play a key role in the natural human innate immunity against pathogens.
Brilacidin Oral Rinse
An oral rinse containing brilacidin, a defensin mimetic, with potential antimicrobial and anti-mucositic activities. Upon rinsing with the brilacidin oral rinse, brilacidin imitates defensin as a human host defense protein (HDP) and binds to and disrupts the bacterial cell membrane. This causes bacterial cell membrane lysis and leakage of cellular cytoplasmic contents. This inhibits bacterial activity and may prevent or treat radiation-induced mucositis.
In 2016, Brilacidin, a novel defensin mimetic, was evaluated as an ocular anti-infective.
Brilacidin COVID-19 Antiviral News
August 12, 2021 - Innovation Pharmaceuticals (OTCQB: IPIX) provided additional information regarding the status of its randomized, double-blind, placebo-controlled Phase 2 clinical trial of Brilacidin for the treatment of moderate-to-severe COVID-19 in hospitalized patients (NCT04784897). The Company is developing Brilacidin for the treatment of COVID-19 under the U.S. FDA Fast Track designation. “Our team is as excited as anyone to learn the results of our Brilacidin COVID-19 clinical trial. Everything is advancing per industry norms and standards,” said Leo Ehrlich, CEO at Innovation. “We look forward to sharing Brilacidin topline data in treating COVID-19 as soon as we have it in hand.”
August 2, 2021 - Innovation Pharmaceuticals provided an update on ongoing antiviral research of Brilacidin, the Company’s defensin-mimetic drug candidate being developed for the treatment of COVID-19 under FDA Fast Track designation by different groups of scientists.
July 22, 2021 - Innovation Pharmaceuticals announced that new Brilacidin antiviral data, based on research conducted by George Mason University / National Center for Biodefense and Infectious Diseases researchers, was presented yesterday, July 21, 2021, at the American Society of Virology’s 40th Annual Meeting. “Brilacidin continues to show a consistent ability in the laboratory to inhibit different contagious viruses, regardless of viral strain and in a cell type-independent manner,” said Aarthi Narayanan, Ph.D., Primary Investigator of Brilacidin at GMU. “Our scientific team looks forward to exploring Brilacidin further as we investigate the breadth of its antiviral profile.”
May 13, 2021 - Innovation Pharmaceuticals (OTCQB: IPIX) announced the filing of its SEC Form 10-Q for the quarter that ended March 31, 2021. During the quarter, the Company made substantive progress in developing Brilacidin, Innovation Pharma’s flagship drug candidate in a new class of compounds called defensin-mimetics.
April 28, 2021 - Innovation Pharmaceuticals announced that enrollment had surpassed 50 percent of the total targeted number of randomized trial participants (~n=120) in its double-blind, placebo-controlled Phase 2 clinical trial of Brilacidin for treatment of moderate-to-severe COVID-19 in hospitalized patients.
April 14, 2021 - Innovation Pharmaceuticals announced that Brilacidin, the Company’s defensin-mimetic drug candidate, was featured in the “Mason Science Series: Rising to the National and International COVID-19 Challenge,” a presentation of George Mason University. And in the article published by the journal Nature: 'The race for antiviral drugs to beat COVID — and the next pandemic.'
April 5, 2021 - Innovation Pharmaceuticals announced an independent Data Monitoring Committee (DMC) completed its scheduled review of interim safety data in the Company’s randomized, double-blind, placebo-controlled Phase 2 clinical trial of Brilacidin for treatment of moderate-to-severe COVID-19 in hospitalized patients. Recruitment was paused upon reaching 25 percent enrollment (30 subjects), and the DMC conducted a pre-specified unblinded safety data review and evaluation. Following their review, the DMC recommended increasing the dosing regimen of Brilacidin from 3 days to 5 days of treatment, as intended per the protocol, which the Company has since implemented. Recruitment for the 5-day treatment regimen has begun. Efficacy data was not reviewed by the DMC and remained blinded.
March 10, 2021 - Innovation Pharmaceuticals reported that a Machine Learning (Artificial Intelligence) model used to screen 1,482 compounds ranked Brilacidin in the top three percent of compounds predicted to be the most effective against SARS-CoV-2, the virus responsible for COVID-19.
March 2, 2021 - Innovation Pharmaceuticals announced a peer-reviewed scientific article—Brilacidin Demonstrates Inhibition of SARS-CoV-2 in Cell Culture—in the journal Viruses. Leo Ehrlich, Chief Executive Officer of Innovation Pharmaceuticals, commented, “Infectious disease experts have noted the next phase in the global fight against COVID-19 will be in developing potent antivirals that directly act on the SARS-CoV-2 virus—which is what Brilacidin has been shown to do in pre-clinical studies.”
February 26, 2021 - Innovation Pharmaceuticals provided additional study details for its ongoing Phase 2 clinical trial assessing Brilacidin as a novel therapeutic in hospitalized patients with COVID-19. Patients are being treated, with recruitment and enrollment progressing at trial sites.
February 9, 2021 - A new review found Brilacidin’s anti-SARS-CoV-2 activity 'suggests that SARS-CoV-2 inhibition in these cell culture models is likely to result from the impact of brilacidin on viral entry and its disruption of viral integrity. Brilacidin demonstrated synergistic antiviral activity when combined with remdesivir. Collectively, our data demonstrate that brilacidin exerts potent inhibition of SARS-CoV-2 against different strains of the virus in cell culture.'
January 14, 2021 - Innovation Pharmaceuticals’ Brilacidin for the Treatment of COVID-19 Receives FDA Fast Track Designation. Laboratory testing at independent laboratories supports Brilacidin’s antiviral ability to safely and potently inhibit SARS-CoV-2 and multiple strains of human coronaviruses. In a human lung cell line against SARS-CoV-2, Brilacidin achieved a Selectivity Index of 426. A molecular screening study of 11,552 compounds also supports Brilacidin as a promising novel coronavirus treatment. Brilacidin antiviral research to date has been limited to laboratory-based experiments.
December 21, 2020 - The U.S. FDA Granted IND Approval for Phase 2 Clinical Trial of Innovation Pharmaceuticals’ Brilacidin for Treating COVID-19. Brilacidin’s potent in vitro inhibition of the Washington and Italian strains of SARS-CoV-2 supports its potential to inhibit emerging coronavirus mutations (variants), such as those in the United Kingdom, Denmark, and South Africa.
November 30, 2020 - Innovation Pharmaceuticals COVID-19 Clinical Trial to Support Additional Development of Brilacidin as a “Pan-Coronavirus” Therapeutic. Additional independent preliminary laboratory research suggests Brilacidin, the Company’s flagship defensin mimetic, can treat other endemic human coronaviruses (H-CoVs), such as those causing common colds, and not just SARS-CoV-2, the novel coronavirus responsible for the ongoing global COVID-19 pandemic.
November 16, 2020 - Innovation Pharmaceuticals announced that an overseas Clinical Trial Application had been submitted to the governing health agency, with a U.S. Investigational New Drug application submitted this week to the FDA. Both these submissions are part of final preparations for the Company’s multinational Phase 2 clinical trial of Brilacidin for COVID-19, which is on track to commence in 2020 upon gaining required approvals.
October 30, 2020 - Innovation Pharmaceuticals and George Mason University’s National Center for Biodefense and Infectious Diseases jointly announced the completion of extensive laboratory testing supporting the anti-SARS-CoV-2 activity of Brilacidin, a defensin-mimetic drug candidate, which is being developed as a potential COVID-19 treatment. “In testing at GMU’s BSL-3 lab, we showed that Brilacidin potently inhibits SARS-CoV-2 in vitro against the live virus. Beyond exhibiting treatment potential for those already infected by COVID-19, Brilacidin’s ability to disrupt viral integrity and block viral entry indicates it has the added potential to prevent infection, upon appropriate formulation, as a prophylactic. I look forward to working with Innovation to investigate further Brilacidin’s antiviral properties,” said Aarthi Narayanan, Ph.D., Associate Professor of Systems Biology in Mason’s College of Science.
Show more
Brilacidin COVID-19 Antiviral Clinical Trial
Clinical Trial NCT04784897: A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19 - Last posted update on March 5, 2021. This Phase 2 study is a randomized, blinded, placebo-controlled, parallel-group design. The target population to be treated are 120 patients with moderate to severe COVID-19, SARS-CoV-2 infection confirmed by positive standard polymerase chain reaction (PCR) test (or equivalent/ other approved diagnostic test) within 4 days before starting study treatment, and hospitalized with respiratory distress but not yet requiring high-level respiratory support.
https://www.precisionvaccinations.com/vaccines/brilacidin-covid-19-therapeutic
As I see it, it is the infection, scar tissue, unchecked congestion in the lungs that is the killer. The lungs are unable to extract oxygen, even though they are on the ventilator.. Brilacidin can provide the knock out punch to the Virus with the Antiviral, the infection treated with the Antibiotic and anti-inflamitory but it can't repair the scarring the lung congestion or the damage done by the Virus,the lungs become non functional, the human Body has to do the repairs . The person treated with the Campassionate use with Brilacidin is still in extreme danger. JMO,as a non medical persons observation.
I would suggest anyone interested in requesting Brilacidin for expanded use and or compassionate use, put the request in writing, send it to their primary Doctor, if they become hospitalized notify their primary Doctor. Additionally a person should provide a copy of the letter sent to the Primary Doctor, to the attending Physician and the Hospital.
I added this stipulation:
should either of us become infected with the Covid19 virus and requires emergency care, we request to be treated under "HR878-Right to Try Act" with a therapeutic treatment approved by the FDA for expanded and Compassionate use known as, Brilacidin.
Just a thought!
If you or someone you know epects to receive Compassionate use authorization, they need to send written instructtions to their primary care Doctor immediately to apply for compassionate use, the Hospital, Doctors employeed by the Hospital, may refuse to apply for compassionate use or make a request to the FDA. I do not know the law but have been told the primary Doctor can over ride the Hospital's refusal.
Agreded but they aren't in the current Chain of Command.
Agreded but they aren't in the current Chain of Command.
CROOKS, THUGS, TRAITORS, MURDERERS ALL SAFE FROM ARREST AND PROSECUTION WHY? BECAUSE THEY ARE CONNECTED, THEY ARE DEMOCRATS.
Gen. Milley Calls Chinese to Warn About Trump!!!
by: Katie Pavlich 2021-09-14 Source: We the People Convention
THIS IS TREASON! WATCH THE VIDEO AND THEN ACT!
Milley is the Woke Joke of a "General" who testified after January 6th that he wanted to learn more about "White Rage" so it is time to show this racist traitor some serious "White Rage" and Black Rage and Hispanic Rage and AMERICAN RAGE!
CALL TO ACTION - ALL Patriots MUST Call their Congressmen TODAY and Demand the following:
WE want to HEAR the phone call(s) between Milley and the Chinese - we will NOT Accept His Word!
General Milley must be COURT MARTIALED - not Fired or Just Allow to Resign
ALL Service Members who participated in the Coup with Him must be COURT MARTIALED
All Members of the Intel Agencies who knew of these acts and did not Inform President Trump MUST be charge with Treason for their Role in Enabling this Coup
Nancy Pelosi and Chuch Schumer Must be Impeached for Enabling and Encouraging this Coup
Biden must be Impeached if he is found to have known this happened and took no Action
This insanity has gone on long enough and WE must Act to defend our Constitution and our Nation! This TREASON MUST NOT GO UNPUNISHED and it is time to raise Holy Hell like NEVER before! Take this Action Today and Start Planning to Take to the Streets if that is what it takes to hold these traitors accountable!
Click Here to Get the Contact Information for Your U.S. House Member and CALL THEM NOW!
Click Here to Get the Contact Information for Your U.S. Senators and CALL THEM NOW!
Click Here to fill out a Department of Defense Inspector General Form Reporting General Milley for Leaking Classified Information to the Chinese
Call YOUR Local Media and Demand they Report on this Historic Story!
New Book says General Milley Committed Treason by Making Call to Chinese about Trump!
by Katie Pavlich, Townhall, September 14, 2021
New reporting from The Washington Post, detailing the contents of a new book, shows General Mark Milley reassured China's People's Liberal Army General Li Zuocheng that he would give the communist country a heads up if President Donald Trump launched an attack in the final months of his presidency. He did so in a series of reported phone calls and reassured Li he would stand between Trump and an attack on Chinese assets.
In a pair of secret phone calls, Gen. Mark A. Milley, the chairman of the Joint Chiefs of Staff, assured his Chinese counterpart, Gen. Li Zuocheng of the People’s Liberation Army, that the United States would not strike, according to a new book by Washington Post associate editor Bob Woodward and national political reporter Robert Costa.
One call took place on Oct. 30, 2020, four days before the election that unseated President Trump, and the other on Jan. 8, 2021.
“General Li, I want to assure you that the American government is stable and everything is going to be okay,” Milley told him. “We are not going to attack or conduct any kinetic operations against you.”
In the book’s account, Milley went so far as to pledge he would alert his counterpart in the event of a U.S. attack, stressing the rapport they’d established through a backchannel.
“General Li, you and I have known each other for now five years. If we’re going to attack, I’m going to call you ahead of time. It’s not going to be a surprise.”
Believing that China could lash out if it felt at risk from an unpredictable and vengeful American president, Milley took action. The same day, he called the admiral overseeing the U.S. Indo-Pacific Command, the military unit responsible for Asia and the Pacific region, and recommended postponing the military exercises, according to the book. The admiral complied.
Milley also summoned senior officers to review the procedures for launching nuclear weapons, saying the president alone could give the order — but, crucially, that he, Milley, also had to be involved. Looking each in the eye, Milley asked the officers to affirm that they had understood, the authors write, in what he considered an “oath.”
In other words, Milley instructed senior officers to obey his orders and to ignore those given by the President Trump, the duly elected commander-in-chief.
https://wethepeopleconvention.org/articles/Milley-Commits-Treason